RT Journal Article
SR Electronic
T1 PNEUMOCOCCAL SEROTYPE DISTRIBUTION AND COVERAGE OF EXISTING AND PIPELINE PNEUMOCOCCAL VACCINES
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.12.24318944
DO 10.1101/2024.12.12.24318944
A1 King, Laura M
A1 Andrejko, Kristin L
A1 Kobayashi, Miwako
A1 Xing, Wei
A1 Cohen, Adam L
A1 Self, Wesley H
A1 Resser, J Jackson
A1 Whitney, Cynthia G
A1 Baughman, Adrienne
A1 Kio, Mai
A1 Grijalva, Carlos G
A1 Traenkner, Jessica
A1 Rouphael, Nadine
A1 Lewnard, Joseph A
YR 2024
UL http://medrxiv.org/content/early/2024/12/13/2024.12.12.24318944.abstract
AB Background Streptococcus pneumoniae (pneumococcus) causes invasive pneumococcal disease (IPD) and non-invasive acute respiratory infections (ARIs). Three pneumococcal conjugate vaccines (PCVs) are recommended in the United States with additional products in clinical trials. We aimed to estimate 1) proportions of IPD cases and pneumococcal ARIs caused by serotypes targeted by existing and pipeline PCVs and 2) annual U.S. pneumococcal burdens potentially preventable by PCVs.Methods We estimated serotype distribution and proportions of non-invasive pneumococcal ARIs (AOM [children only], sinusitis, non-bacteremic pneumonia) and IPD attributable to serotypes targeted by each PCV using Markov chain Monte Carlo approaches incorporating data from studies of serotype distribution in ARIs and Active Bacterial Core Surveillance (ABCs) data. We then estimated annual numbers of outpatient-managed pneumococcal ARIs, non-bacteremic pneumococcal pneumonia hospitalizations, and IPD cases potentially preventable by PCVs in the United States by multiplying pneumococcal disease incidence rates by PCV-targeted proportions of disease and vaccine effectiveness estimates.Results In children, PCV15, PCV20, PCV24, PCV25, and PCV31 serotypes account for 16% (95% confidence interval: 15–17%), 31% (30–32%), 34% (32–35%), 43% (42–44%), and 68% (67–69%) of pneumococcal acute otitis media cases, respectively. In adults, PCV15, PCV20, PCV21, PCV24, PCV25, and PCV31 serotypes account for 43% (38–47%), 52% (47–57%), 69% (64–73%), 65% (61–70%), 62% (57–67%), and 87% (83–90%) of pneumococcal non-bacteremic pneumonia cases. For IPD, 42–85% of pediatric and 42–94% of adult cases were due to PCV-targeted serotypes. PCV-preventable burdens encompassed 270 thousand–3.3 million outpatient-managed ARIs, 2–17 thousand non-bacteremic pneumonia hospitalizations, and 3–14 thousand IPD cases in the United States annually.Conclusions Across pneumococcal conditions, coverage and preventable burdens were lowest for PCV15 and highest for PCV31, with PCV21 also targeting sizeable burdens of adult disease. Serotype distribution across syndromes may inform vaccine formulations and policy.Competing Interest StatementLMK reports consulting fees from Merck Sharpe & Dohme for unrelated work and Vaxcyte for related and unrelated work and reports support for attending a meeting from UC Berkeley Center for Effective Global Action. CGG reports consulting fees from Merck & Co., Inc and research funding from NIH, CDC, AHRQ, FDA, and Campbell Alliance/Syneos Health for unrelated work. NR reports research funding from Merck, Sanofi, Pfizer, Vaccine Company, Immorna, Quidel and Lilly for unrelated work, reports consulting fees from Krog, reports honoraria from Virology Education and Medscape, reports support for attending a meeting from Sanofi and Moderna, reports participation in advisory boards for Moderna, Sanofi, Seqirus, Pfizer, EMMES, ICON, and Micron, and reports leadership roles with ARLG, TMRC, CDC-Pertussis challenge, and Clinical Infectious Diseases. JAL reports research grants from Pfizer and Merck Sharpe & Dohme for unrelated work and consulting fees from Pfizer, Merck, Sharpe & Dohme, Vaxcyte, Seqirus Inc., and Valneva SE for unrelated work and Vaxcyte for related work, and reports support for attending a meeting from Vaxcyte. All other authors reported no conflicts of interest.Funding StatementThis work was supported by the Centers for Disease Control and Prevention [21IPA2111845 to JAL] and the National Institutes of Health [1F31AI174773-01 to LMK]. The National Institutes of Health had no input into the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The Centers of Disease Control and Prevention was involved through co-author participation the design and conduct of the study; analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health and the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData produced in the present work are contained in the manuscript.